Picularium, LLC 3
3 · Relay Therapeutics, Inc. · Filed Jul 15, 2020
Insider Transaction Report
Form 3
Picularium, LLC
10% Owner
Holdings
Series A Preferred Stock, $0.001 par value per share
→ Common Stock, $0.001 par value per share (9,999,999 underlying)Series C Preferred Stock, $0.001 par value per share
→ Common Stock, $0.001 par value per share (1,651,471 underlying)
Footnotes (3)
- [F1]Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, is convertible into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock"), at any time at the option of the holder. Shares of Series A Preferred Stock will automatically convert into shares of the Common Stock upon the closing of the Issuer's initial public offering of Common Stock. The current conversion rate is .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
- [F2]Each share of Issuer Series C Preferred Stock, $0.001 par value per share, is convertible into shares of Common Stock at any time at the option of the holder. Shares of Series C Preferred Stock will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock. The current conversion rate is .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
- [F3]David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any.